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OBJECTIVES The goal of this study was to determine whether carotid angioplasty and stenting (CAS) is
equivalent to carotid endarterectomy (CEA) in patients with symptomatic carotid stenosis
70% by a randomized, controlled trial in a community hospital.
BACKGROUND Carotid angioplasty and stenting has been suggested to be as effective as CEA for treatment
of symptomatic carotid artery stenosis.
METHODS A total of 104 patients presenting with cerebrovascular ischemia ipsilateral to carotid stenosis
were selected randomly for CEA or carotid stenting and followed for two years.
RESULTS Stenosis decreased to an average of 5% after CAS. The patency of the reconstructed artery
remained satisfactory regardless of the technique as determined by sequential ultrasound. One
death occurred in the CEA group (1/51); one transient ischemic attack occurred in the CAS
group (1/53); no individual sustained a stroke. The perception of procedurally related pain/
discomfort was similar. Hospital stay was similar, although the CAS group tended to be
discharged earlier (mean 1.8 days vs. 2.7 days). Complications associated with CAS prolonged
hospitalization when compared with those sustaining a CEA-related complication (mean  5.6
days vs. 3.8 days). Return to full activity was achieved within one week by 80% of the CAS group
and 67% of the patients receiving CEA. Hospital charges were slightly higher for CAS.
CONCLUSIONS Carotid stenting is equivalent to CEA in reducing carotid stenosis without increased risk for
major complications of death/stroke. Because of shortened hospitalization and convalescence,
CAS challenges CEA as the preferred treatment of symptomatic carotid stenosis if a
reduction in costs can be achieved. (J Am Coll Cardiol 2001;38:1589–95) © 2001 by the
American College of Cardiology
The efficacy of endarterectomy for the treatment of patients
with symptomatic high-grade stenosis of the extracranial
carotid artery has been established through a series of
randomized, controlled trials (1–4). The absolute reduction
in the occurrence of cerebral ischemic events is dependent,
however, on perioperative complication rates (5,6). A com-
bined stroke (major or minor) and death rate exceeding 6%
for patients with symptomatic stenosis eliminates the ben-
efit of stroke reduction gained through operation. Although
varying according to operator and hospital experience (7),
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the overall incidence of major disabling stroke approaches
2% with mortality rates of 1% (8,9), thereby supporting
the therapeutic advantages of carotid endarterectomy
(CEA) in treating symptomatic carotid stenosis. Despite
this reduction in serious complications, CEA has limita-
tions (10–14). Minor strokes and/or complications remain
significant and can be disabling. Cranial or cervical nerve
palsies occur in 7.6% to 27% of patients undergoing CEA
(15–17). Complications associated with concurrent cardiac
disease and hypertension occur perioperatively in about 8%
of patients (18). In addition, individuals with contralateral
carotid occlusion or advanced coronary vascular disease are
considered poor candidates for CEA (1,19–22). Other
well-known anatomical considerations, which increase mor-
bidity and mortality, include the presence of an extremely
high carotid bifurcation (C1 to C2), tracheotomy, recurrent
stenosis after previous CEA and radical neck dissection with
or without radiation-induced carotid stenosis.
The advent of percutaneous endovascular techniques has
the potential for being safer, less traumatic and more
cost-effective in patients with symptomatic carotid occlusive
disease. The therapeutic advantage of carotid angioplasty
and stenting (CAS) has been demonstrated in patients with
contralateral occlusion, restenosis and surgically inaccessible
lesions (23–25). Although it has been suggested that CAS is
an acceptable (26–30), if not preferred, alternative to CEA,
the clinical experience has been less enthusiastic. Data
accrued from various centers report a major stroke and death
rate of 4.7% after CAS (30). Others report a “minor” stroke
rate associated with CAS of 6.5% compared with a CEA-
related risk of 0.6% (31). Although these complications may
be lessened through operator experience after an as yet to be
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defined “learning curve” and optimal patient selection, the
theoretical benefits of endoluminal revascularization in
treating symptomatic or asymptomatic carotid stenosis have
not been realized fully or documented in randomized
comparative trials. Indeed, the only published randomized
study of CAS versus CEA was stopped because of the
occurrence of strokes, three of which were considered major,
in five of the seven patients who underwent CAS (32).
The purpose of this prospective, randomized trial was to
compare the efficacy and benefits of CAS with CEA in the
treatment of symptomatic carotid stenosis in a community
hospital.
METHODS
This two-arm randomized clinical trial was approved by the
Institutional Review Board to include patients experiencing
symptoms and/or signs of cerebral ischemia confined to the
ipsilateral internal carotid artery. All patients were informed
that the Food and Drug Administration has not approved
deployment of stents within the carotid artery for the
treatment of carotid stenosis. Patients with symptoms of
vertebral-basilar insufficiency or intracranial occlusive dis-
ease shown by cerebral angiography were excluded. The
inclusion criteria included those sustaining events confined
to the carotid circulation within three months of evaluation;
70% stenosis of the ipsilateral carotid bifurcation as
determined by the North American Symptomatic Carotid
Endarterectomy Trial (NASCET) (33); anticipated life
expectancy of five years; willingness to complete treatment
within two weeks and ability to sign informed consent.
Exclusion criteria included: National Institute of Health
(NIH) stroke scale of4; cardiac arrhythmia; allergy and/or
sensitivity to aspirin, heparin, ticlopidine or clopidogrel;
history of bleeding diathesis or coagulopathy or history of
intracranial hemorrhage within two months of randomiza-
tion. A total of 104 individuals met these criteria, agreed to
participation and were selected randomly to undergo CEA
(51 individuals) or CAS (53 individuals). The presence of
contralateral total occlusion and/or the angiographic ap-
pearance of the stenotic lesion were not factors in treatment
selection. All patients received 325 mg aspirin and 75 mg
clopidogrel before CAS or CEA. A neurologist (T. C.) and
the research clinical nurse coordinator (L. B.) provided
independent oversight and neurologic examination before
and subsequent to each procedure.
Carotid endarterectomy was performed using standard
operative techniques under general anesthesia with intraop-
erative electroencephalogram monitoring. All patients were
observed in intensive care for 24 h.
Carotid angioplasty and stenting was performed using
a standard percutaneous retrograde femoral approach via
an 8F Super-S Arrowflex sheath (Arrow International, Inc.,
Reading, Pennsylvania). After heparinization with 100 /kg,
carotid angiography was performed with a 5F/125-cm VTK
(Cook, Inc.) catheter over a 0.035-in angled-tip glide wire.
Subsequent to guiding angiography, an 0.18-in Steel-core
wire (Guidant-ACS, Inc., Indianapolis, Indiana) was placed
in the external carotid artery for support. The Arrowflex
sheath then was advanced over either the VTK catheter or
the Arrowflex dilator into the common carotid artery.
Activated clotting time (ACT) was maintained 300.
Distal protection was not used in any case. Although not
routinely used, ReoPro (0.25 mg/kg bolus over 20 min
followed by a continuous infusion of 0.125 g/kg/min for
12 h to a maximum of 10 g/min) was administered to
three individuals who sustained cerebral vascular accidents
(CVA) with persistent defects (NIH  4) associated with
ulcerative lesions and possible residual thrombus. In all
cases, the stenosis was crossed using a 0.014-in Sport wire
(Guidant-ACS, Inc.) and placed in the petrous portion of
the internal carotid artery. All stenoses were predilated with
a 4.0  20 mm Symmetry balloon (Medi-Tech, BSC, Inc.)
inflated to 8 atms for 5 s before placement of a 10 20 mm
Wallstent (Boston Scientific, Inc.). Postdilation was
completed with an appropriately sized balloon meeting a
balloon:artery ratio of 1:1 by visual estimate. Pan cerebral
angiography was performed before withdrawal of the Ar-
rowflex sheath from the common carotid artery.
A 6F femoral venous sheath was placed at the initiation
of the procedure for placement of a temporary pacemaker if
bradycardia was observed. Systolic arterial pressure was
maintained between 120 mm Hg to 160 mm Hg through-
out the procedure. All patients were admitted and observed
in the neurovascular intensive care for 24 h. The sheaths
were removed when the ACT was 170.
Carotid duplex scanning was performed within 24 h of
either procedure and at 1, 3, 6, 12 and 24 months and
expressed as the ratio of internal carotid artery/common
carotid artery velocity. Sequential neurologic examinations,
Rankin and Barthel scorings were performed concurrent
with Duplex scanning. Magnetic resonance imaging (MRI)
was obtained at 6 and 12 months to detect the presence of
asymptomatic ischemic events in the distribution of the
treated vessel (34).
Perception of pain was assessed in accordance with
guidelines commissioned by the Agency for Health Care
Policy and Research (35). No specific posthospitalization
instructions were provided in reference to activities; each
individual determined return to “full activity.”
Abbreviations and Acronyms
ACT  activated clotting time
CAS  carotid angioplasty and stenting
CEA  carotid endarterectomy
CVA  cerebral vascular accident
MRI  magnetic resonance imaging
NIH  National Institute of Health
NASCET  North American Symptomatic Carotid
Endarterectomy Trial
TIA  transient ischemic attack
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Hospital variable costs included operating room or cath-
eterization laboratory, nursing, pharmacy, laboratory and
radiology. Professional charges were not assessed for stent-
ing; hence, no physician’s fees were included in determina-
tion of any costs or charges. Costs/charges for the single
patient requiring amputation necessitated by complications
attendant with femoral artery access were not included.
Results are expressed as average  SEM. Statistical
comparisons were performed using Student t test. Two-way
repeated measures of analysis of variance were used to
compare sequential testing of carotid duplex scanning. A p
value of 0.05 was considered statistically significant.
RESULTS
Demographics. The inclusion criteria, average ages and
numbers of men and women of those randomized for CEA
or CAS were similar (Table 1). The most common present-
ing event was a TIA. Those sustaining a CVA were
functionally independent (NIH scores of 4 and Barthel
Index 90). No patient experienced speech or comprehen-
sion dysfunction. Risk factors for stroke included hyperten-
sion, elevated cholesterol, smoking and diabetes. More than
two risk factors were observed in more than 50% (70/104) of
patients.
Results of treatment. Most patients (87/104) were treated
within one month (range: 7 to 42 days.) of the presenting
symptom. All received definitive treatment by six weeks.
Diagnostic cerebral angiography indicated the average pre-
treatment stenosis in the CEA group (88.2  13.2%) to be
similar (p  0.05) to the CAS group (82.4  7.1%). The
mean cross-sectional diameter as determined by the greatest
stenosis observed on anteroposterior, lateral or oblique
angiographic view was 1.6  1.1 mm (range: 0.8 mm to
2.4 mm) in the CAS group and 1.7  0.46 mm (range:
1.0 mm to 3.0 mm) in those undergoing CEA. The
contralateral, asymptomatic carotid artery was found to have
50% stenosis in 70/104 patients, although total occlusion
was observed in five and two individuals undergoing CAS or
CEA, respectively. The average postangioplasty and stent-
ing stenosis decreased to 5.0  2.7% (range: 0% to 10%).
The 24-month patency of the reconstructed artery remained
satisfactory as determined by carotid ultrasound (Fig. 1). No
MRI evidence of asymptomatic focal cerebral ischemia was
found in any patient (data not shown).
Complications. No patient sustained a CVA, although
one individual died from an immediate postoperative myo-
cardial infarction subsequent to CEA (Table 2). This was
the only procedurally related mortality experienced during
this study. One patient experienced transient confusion
associated with left sensory loss subsequent to postdilation
of the stent that resolved within 10 min with elevation of
the systolic blood pressure. Complications associated with
CEA included wound hematoma requiring re-exploration
(one patient) and peripheral nerve injury manifest as hoarse-
ness (one patient) or lower facial and diminished sensations
in the neck (three patients). These nerve injuries resolved
within three months.
The most common occurrence associated with CAS was
transient bradycardia (7/53) and/or hypotension (12/53)
concurrent with angioplasty as a result of carotid body
stimulation. None persisted more than 24 h. Initially, a
Table 1. Baseline Characteristics of Study Patients
CAS
(n  53)
CEA
(n  51)
Mean age (yrs) 66.4 (36–78) 69.6 (56–81)
Presenting symptom
Stroke (NIH  4) 9 8
Transient ischemia 32 33
Amaurosis fugax 12 10
Risk factors
Hypertension 45 48
Diabetes mellitus 19 12
Cholesterol (200) 34 24
Smoking 38 40
2 risk factors 38 32
Coronary vascular disease 39 31
Family history
Stroke 27 31
Cardiac disease 48 48
CAS  carotid angioplasty and stenting; CEA  carotid endarterectomy.
Figure 1. Patency of carotid artery before revascularization and after 3, 6,
9, 12, 18 and 24 months expressed as average internal carotid artery/
common carotid artery (ICA/CCA) systolic ratio. CAS  carotid angio-
plasty and stenting; CEA  carotid endarterectomy.
Table 2. Complications
CAS CEA
Death/cerebral ischemia
Death 0 1
Stroke 0 0
Transient cerebral ischemia 1 0
Other
Arterial thrombosis/amputation 1 0
Hematomas requiring treatment 3 1
Cranial/cervical nerve injury 0 4
Bradycardia (temporary pacing) 7 0
Hypotension (requiring treatment) 12 3
CAS  carotid angioplasty and stenting; CEA  carotid endarterectomy.
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temporary pacemaker was inserted prophylactically. How-
ever, in efforts to contain cost and due to infrequent use, this
has been abandoned. Currently, severe and/or prolonged
bradycardia and/or flux in blood pressure were treated
pharmacologically. These events are anticipated and fre-
quently resolve without treatment. Complications associ-
ated with CAS were contingent with femoral artery access
similar to other routine interventional approaches used for
coronary artery disease (36). Retroperitoneal hemorrhage
occurred in the three patients who received the platelet
IIb/IIIa receptor antibody, abciximab (ReoPro, Eli Lilly and
Co., Indianapolis, Indiana) in conjunction with heparin.
This complication can be avoided by adhering closely to
recommendations for the use of heparin with this mono-
clonal antibody provided by the Evaluation in Percutaneous
Transluminal Coronary Angioplasty to Improve Long-term
Outcome with Abciximab Glycoprotein IIa/IIIb Blockade
(EPILOG) protocol (37). One individual with previously
undiagnosed advanced generalized peripheral vascular oc-
clusive disease sustained popliteal artery thrombosis, which
necessitated below-the-knee amputation. This was the only
major complication in the CAS group.
Length of hospital stay. The length of hospitalization was
similar for both groups, although those undergoing CAS
without complication tended to be discharged sooner (Table
3). As the study progressed, patients in the CEA group
remained in the hospital for shorter periods, most being
discharged the day after surgery. Forty-four patients (44/53)
in the CAS group (83%) and 34 patients (34/51) in the
CEA group (67%) were discharged from the hospital the
day after the procedure. Excluding the single patient requir-
ing below-the-knee amputation whose hospitalization ex-
tended to 68 days, overall hospital stays tended to be shorter
in the CAS group (2.6  1.6 days vs. 3.7  3.1 days).
Nevertheless, complications prolonged hospital care slightly
more in the CAS group (5.6  3.7 days vs. 3.8  3.5 days).
The primary complication associated with CAS was related
to femoral artery access (3/53), which prolonged hospital-
ization because of continued bed rest and/or transfusion.
Cranial/peripheral nerve injuries associated with CEA
(4/51) did not prolong hospitalization. Hospitalization was
extended secondary to concurrent or subsequent coronary
bypass surgery in five patients. This procedure added an
average of 10  2 days to hospitalization. Neither CAS nor
CEA afforded an advantage in terms of shortened stay in
this small group of patients.
Patient’s perception of pain and return to activity. The
perception of pain was similar in both groups; neither
experienced pain beyond a rating of 5/10 (Table 4). Most
symptoms resolved by one month. Return to full activity was
achieved within one week by 43 of the 53 patients under-
going CAS and 34 of the 51 patients randomized to CEA.
All individuals in the CEA group resumed full activity by
one month. However, complications in the CAS group
significantly prolonged convalescence (57 to 120 days).
Cost/charges. Variable costs reflect the actual expenditures
of performing a specific procedure, thus provide an accurate
accounting of CEA and CAS. The total variable costs
associated with CAS and CEA are similar (p  0.89)
(Table 5). As anticipated, individual hospital costs and
charges resulting from the occurrence of complications
varied widely, although they were higher for the CAS group
secondary to prolonged hospitalization. Charges to patients,
which did not include any professional fees, were higher in
the CAS group (p  0.01).
DISCUSSION
Endovascular technology has advanced to include treatment
of carotid occlusive disease (23,24,26–29,38). Although
proponents suggest that stenting may be effective in reduc-
ing carotid stenosis, its use has been recommended without
testing its “clinical equipoise” (39) against the standard of
care, endarterectomy. The single published randomized
study designed to address this issue was suspended because
of significant numbers of disabling strokes associated with
Table 3. Days Length of Hospital Stay*
CAS CEA
All patients 5.2  11.4 days (1–68)† 3.7  3.1 days (1–14)
Without complications 1.8  0.58 days (1–4) 2.7  1.2 days (1–13)
With complications 13.3  21 days (3–68)† 3.8  3.5 days (1–14)
*Avg  SEM (range); †Exempting the single patient with major vascular complication, overall length of stay for CAS  2.6 
1.6 days. Average length of stay for patients undergoing CAS who experienced other complications  5.6  3.7 days (3–11).
CAS  carotid angioplasty and stenting; CEA  carotid endarterectomy.
Table 4. Perception of Perioperative Pain and Activity
CAS CEA
Pain scale (0–10)
24 h postprocedure (avg) 1.2 (range 0–5) 2.7 (range 0–5)
1 month postprocedure 1.0 (0–4) 1.0 (0–4)
Return to full activity (average days)
Without complication 12 days (2–30) 16 days (7–30)
With complications 120 days (57–140) 21 days (9–30)
CAS  carotid angioplasty and stenting; CEA  carotid endarterectomy.
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stenting (32). Other multicenter prospective, randomized
trials comparing CAS with CEA have been suspended (40)
or have yet to be initiated (41). This report presents initial
observations of a clinical trial designed to investigate the
safety and effectiveness of carotid stenting compared with
CEA in treating symptomatic carotid occlusive disease in a
community hospital.
Equipoise of stenting and endarterectomy. Our results
agree that carotid stenting is equally as effective as CEA in
correcting and maintaining postprocedure patency of ca-
rotid stenosis (24,26,28,42). Equipoise is further supported
by MRI, indicating that no asymptomatic ischemic events
occurred in the distribution of the treated vessel subsequent
to either revascularization technique (data not shown). The
occurrence of major or minor stroke or death associated
with CAS or CEA was well within the limits of acceptable
risk delineated by the NASCET (1,4) and Asymptomatic
Carotid Arteriosclerosis study (43) yet markedly differed
from previous reports of nonrandom series indicating a risk
for major or minor stroke associated with CAS approaching
6% (31). Although the “learning curve” for CAS is about 50
cases (31,42), the occurrence rates for serious complications
in series involving an excess of 100 patients is higher than
those associated with CEA (26,28,31,43,44). The low
number of neurologic complications observed in this trial
reflects a “cerebral endovascular team” comprised of neuro-
surgeons possessing skills in endarterectomy and catheter-
based techniques, experienced interventional cardiologists
and neurologists.
Economic issues of carotid stenting versus endarterec-
tomy. Economic evaluation of stroke prevention and treat-
ment is an important factor in the heath care sector
(45–47). Thus, the deference toward evidence-based med-
icine now includes a demand for “cost-effectiveness” of new
and existing technologies. This trial addresses these issues as
characterized by length of hospital stay, the return to full
activity, patient’s perception of pain associated with the
procedure and hospital costs. The occurrence of major or
minor stroke was not observed in this trial regardless of the
revascularization procedure. Thus, in contradistinction to
Jordan et al. (31), these cerebrovascular complications can-
not be deployed in an economic argument favoring CEA
over CAS. Initially, stenting resulted in a shortened hospital
stay with most patients being discharged within 24 h.
However, based on our experience and that of others, that
complications associated with endarterectomy occur within
6 h, a growing tendency toward shorter hospitalization after
CEA has evolved (48–50). Most patients undergoing CEA
are discharged within 24 h. Although, the theoretical
advantage of “early” hospital discharge supposed through
percutaneous technology has yet to be determined, hospital
stay subsequent to CAS may be lessened in the future
through miniaturization of technology and routine use of
arterial closure devices.
As expected, hospitalization is prolonged by procedural
complications. Cranial or peripheral nerve injury or neck
hematomas that are rapidly recognized and appropriately
treated do not influence hospital stay (1,16); however, the
occurrence of clinically significant retroperitoneal hemor-
rhage does prolong hospitalization (36). Although antico-
agulation is necessary, the paradigm used in stenting prob-
ably can be lessened because most cerebral ischemic events
are associated with post-stent dilation, at which time
atheromatous material may be released from the arterial wall
rather than hematologic emboli (51). Routine use of distal
protection devices in conjunction with less anticoagulation
may reduce the risk of both excessive retroperitoneal and
intraprocedural ischemic events. However, the addition of
distal protection devices designed to prevent cerebral em-
bolization of atheromatous material actually may increase
cost/charges.
The evaluation of pain and return to full activity also
judges the economic efficiency of a procedure. The frequent
bias that “open” surgical techniques are less well tolerated in
terms of pain and discomfort than percutaneous approaches
is not supported by this trial. Both procedures seem equally
well tolerated in terms of pain and discomfort. Moreover,
return to full activity was achieved in about two weeks
regardless of the procedure. However, return to full activity
was delayed by complications particularly after CAS. Pain
associated with groin complications is more limiting than
those involving incisions in the neck in terms of active daily
living.
Whereas, this study shows that the effectiveness of CAS
is equivalent to CEA in terms of the ability to correct
symptomatic carotid stenosis without increased risk for
major or minor stroke, fiscal considerations tend to favor
CEA (52). Although pharmacy and “routine” hospital costs
and charges may be similar, expenditures associated specif-
ically with cardiac catheterization laboratories compared
with standard operating rooms are higher. Stents, angio-
plasty balloons, catheters, guiding wires, sheaths and the use
of temporary pacemakers are costly and nonreusable. If the
use of a distal protection device becomes a “standard of
care,” the costs will escalate further. These data suggest that,
from a perspective of an economic evaluation, the potential
Table 5. Comparison of Variable Costs/Patient Charges*
Total Costs
Nursing
Costs
Cath/OR
Lab
Pharmacy
Costs
Lab
Costs
Radiology
Costs
Charges (Excluding
Doctor Fees)
CAS 4,077  460 327  39 3,550  286 66  16 81  26 105  11 6,653  367
CEA 3,415  1,289 1,187  101 1,159  359 470  229 79  41 108  58 5,594  166
*Expressed as Avg  SEM.
CAS  carotid angioplasty and stenting; CEA  carotid endarterectomy; OR  operating room.
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effect gained through percutaneous carotid stenting may be
lessened by increased incremental cost/charges.
Study limitations. This trial is limited to a single institu-
tion, and a select “team” with experience in cerebral vascular
disease and endovascular techniques, thus, cannot advocate
that CAS replace CEA as a primary revascularization
procedure in patients with symptomatic carotid stenosis.
However, it is the first randomized prospective study to
demonstrate that carotid angioplasty and stenting is equiv-
alent to endarterectomy for the treatment of symptomatic
carotid stenosis without added risk for major or minor
stroke. If the economic constraints of incremental costs
associated with stenting can be overcome, this trial indicates
that CAS has reached clinical equipoise with CEA.
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